CERTIFICATE NUMBER:
480166-104693690
CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1)
, (2)
Part 1
Issued following an inspection in accordance with Art. 63 of Regulation (EU) 536/2014 as amended Art. 94(1) of Regulation (EU) 2019/6 as amended Art. 111(5) of Directive 2001/83/EC as amended
The competent authority of Austria confirms the following:
The manufacturer: Fresenius Kabi Austria GmbH
Site address:
Hafnerstrasse 36, Graz, Styria, 8055, Austria
OMS Organisation Id. / OMS Location Id.: ORG-100000614 / LOC-100001746
Has been inspected under the national inspection programme in connection with manufacturing authorisation no.
480166
in accordance with Art. 88 of Regulation (EU) 2019/6, Art. 61 of Regulation (EU) No 536/2014 and Art. 40 of Directive 2001/83/EC, transposed in the following national legislation:§ 63 Medicines Act (Arzneimittelgesetz) and Ordinance 2009 (Arzneimittelbetriebsordnung 2009).
From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on
2025-07-18
, it is considered that it complies with:
The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)
The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EEC. (3)
This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.
The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.
__________________________________________________________________________________________________________________________
(1) The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC, Art. 80(5) of Directive 2001/82/EC and Art. 111(5) of Directive 2001/83/ECis also applicable to importers. (2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate. (3) These requirements fulfil the GMP recommendations of WHO.
Part 2
Human Medicinal Products
Human Investigational Medicinal Products
Veterinary Medicinal Products
1 MANUFACTURING OPERATIONS
1.1 Sterile products
1.1.1 Aseptically prepared (processing operations for the following dosage forms)
1.1.1.1 Large volume liquids 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids 1.1.1.6 Other: Stoffe mit hormoneller Wirkung, Antibiotika / Substances with hormonal activity, antibiotics, Stoffe mit hormoneller Wirkung, Antibiotika / Substances with hormonal activity, antibiotics(en) 1.1.2 Terminally Sterilised (processing operations for the following dosage forms)
1.1.2.1 Large volume liquids 1.1.2.3 Small volume liquids 1.1.2.5 Other: Stoffe mit hormoneller Wirkung, Antibiotika / Substances with hormonal activity, antibiotics, Stoffe mit hormoneller Wirkung, Antibiotika / Substances with hormonal activity, antibiotics(en) 1.1.3 Batch certification
1.2 Non-sterile products
1.2.2 Batch certification
1.3 Biological medicinal products (list of product types)
1.3.1 Biological medicinal products (list of product types)
1.3.1.1 Blood products 1.3.1.2 Immunological products 1.3.1.5 Biotechnology products 1.3.1.6 Human or animal extracted products 1.3.1.8 Other: Biosimilars / Biosimilars, Abfüllen von Arzneimitteln aus PMF und non-PMF Plasma aus USA im Rahmen eines Drittlandfraktionierprogramms / Filling of medicinal products derived from PMF and non-PMF Plasma as part of a third country contract fractionation program with USA, Biosimilars / Biosimilars, Abfüllen von Arzneimitteln aus PMF und non-PMF Plasma aus USA im Rahmen eines Drittlandfraktionierprogramms / Filling of medicinal products derived from PMF and non-PMF Plasma as part of a third country contract fractionation program with USA(en) 1.3.2 Batch Certification (list of product types)
1.3.2.1 Blood products 1.3.2.2 Immunological products 1.3.2.5 Biotechnology products 1.3.2.6 Human or animal extracted products 1.3.2.8 Other: Biosimilars / Biosimilars, Abfüllen von Arzneimitteln aus PMF und non-PMF Plasma aus USA im Rahmen eines Drittlandfraktionierprogramms / Filling of medicinal products derived from PMF and non-PMF Plasma as part of a third country contract fractionation program with USA, Biosimilars / Biosimilars, Abfüllen von Arzneimitteln aus PMF und non-PMF Plasma aus USA im Rahmen eines Drittlandfraktionierprogramms / Filling of medicinal products derived from PMF and non-PMF Plasma as part of a third country contract fractionation program with USA(en)
1.4 Other products or manufacturing activity
1.4.3 Other: Parametrische Freigabe/ Parametric release(en)
1.5 Packaging
1.5.2 Secondary packaging
1.6 Quality control testing
1.6.2 Microbiological: non-sterility
1.6.3 Chemical/Physical
1.6.4 Biological
2 IMPORTATION OF MEDICINAL PRODUCTS
2.1 Quality control testing of imported medicinal products
2.1.2 Microbiological: non-sterility
2.1.3 Chemical/Physical
2.1.4 Biological
2.2 Batch certification of imported medicinal products
2.2.1 Sterile products
2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised 2.2.2 Non-sterile products
2.2.3 Biological medicinal products
2.2.3.2 Immunological products 2.2.3.5 Biotechnology products 2.2.3.6 Human or animal extracted products 2.2.3.8 Other: Biosimilars / Biosimilars, Biosimilars / Biosimilars(en)
2.3 Other importation activities
2.3.1 Site of physical importation
2.3.2 Importation of intermediate which undergoes further processing
Clarifying remarks (for public users):